Literature DB >> 12915103

Toxicokinetics of the nerve agent (+/-)-VX in anesthetized and atropinized hairless guinea pigs and marmosets after intravenous and percutaneous administration.

Marcel J van der Schans1, Brenda J Lander, Herma van der Wiel, Jan P Langenberg, Hendrik P Benschop.   

Abstract

In continuation of our investigations on the toxicokinetics of the volatile nerve agents C(+/-)P(+/-)-soman and (+/-)-sarin, we now report on the toxicokinetics of the rather nonvolatile agent (+/-)-VX. A validated method was developed to determine blood levels of (+/-)-VX by means of achiral gas chromatography at blood levels > or =10 pg/ml. The ratio of the two enantiomers of VX in blood could be measured at levels > or =1 ng/ml by using chiral HPLC in combination with off-line gas chromatographic analysis. In order to obtain basic information on the toxicokinetics of (+/-)-VX, i.e., under conditions of 100% bioavailability, the blood levels of this agent were measured in hairless guinea pigs at iv doses corresponding with 1 and 2 LD50. The derived AUCs indicate a reasonable linearity of the toxicokinetics with dose. Also, the toxicokinetics in marmoset primates was studied at an absolute iv dose corresponding with 1 LD50 in the hairless guinea pig which led to approximately the same levels of (+/-)-VX in blood as observed at 2 LD50 in the hairless guinea pig. Finally, the toxicokinetics of (+/-)-VX were measured in hairless guinea pigs via the most relevant porte d' entrée for this agent, which is the percutaneous route at a dose corresponding with 1 LD50 (pc). Large variations were observed between individual animals in the rate of penetration of (+/-)-VX and in concomitant progression of AChE inhibition in blood of these animals. Blood levels of (+/-)-VX increased gradually over a 6-h period of time. After a 7-h penetration period, the total AUC corresponded with 2.5% bioavailability relative to iv administration. In contrast with the G-agents C(+/-)P(+/-)-soman and (+/-)-sarin, stereospecificity in the sequestration of the two enantiomers of (+/-)-VX is not a prominent phenomenon. It appears that (+/-)-VX is substantially more persistent in vivo than the two G-agents. This persistence may undermine the efficacy of pretreatment with carbamates of percutaneous intoxication in particular due to gradual replacement of carbamate on AChE by (+/-)-VX, whereas classical treatment of intoxication with oximes is hampered by the short persistence of oximes relative to the agent.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12915103     DOI: 10.1016/s0041-008x(03)00216-3

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  10 in total

Review 1.  Organophosphorus pesticide determination in biological specimens: bioanalytical and toxicological aspects.

Authors:  Sofia Soares; Tiago Rosado; Mário Barroso; Duarte Nuno Vieira; Eugenia Gallardo
Journal:  Int J Legal Med       Date:  2019-07-12       Impact factor: 2.686

2.  HI-6 assisted catalytic scavenging of VX by acetylcholinesterase choline binding site mutants.

Authors:  Nikolina Maček Hrvat; Suzana Žunec; Palmer Taylor; Zoran Radić; Zrinka Kovarik
Journal:  Chem Biol Interact       Date:  2016-04-12       Impact factor: 5.192

3.  Post-exposure therapy with recombinant human BuChE following percutaneous VX challenge in guinea-pigs.

Authors:  Helen Mumford; John K Troyer
Journal:  Toxicol Lett       Date:  2011-05-19       Impact factor: 4.372

4.  Percutaneous exposure to VX: clinical signs, effects on brain acetylcholine levels and EEG.

Authors:  Marloes J A Joosen; Marcel J van der Schans; Herman P M van Helden
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

5.  Evidence of VX nerve agent use from contaminated white mustard plants.

Authors:  Matthew R Gravett; Farrha B Hopkins; Adam J Self; Andrew J Webb; Christopher M Timperley; Matthew J Baker
Journal:  Proc Math Phys Eng Sci       Date:  2014-08-08       Impact factor: 2.704

6.  Extended retrospective detection of regenerated sarin (GB) in rabbit blood and the IMPA metabolite in urine: a pharmacokinetics study.

Authors:  Merav Blanca; Avital Shifrovitch; Shlomit Dachir; Shlomi Lazar; Maor Elgarisi; Hagit Prihed; Shlomi Baranes; Inbal Egoz; Meir Avraham; Hani Dekel Jaoui; Ohad Mazor; Shai Dagan; Avi Weissberg
Journal:  Arch Toxicol       Date:  2021-05-25       Impact factor: 5.153

Review 7.  Organophosphorus compounds and oximes: a critical review.

Authors:  Franz Worek; Horst Thiermann; Timo Wille
Journal:  Arch Toxicol       Date:  2020-06-06       Impact factor: 5.153

8.  In Vitro Interaction of Organophosphono- and Organophosphorothioates with Human Acetylcholinesterase.

Authors:  Franz Worek; Horst Thiermann; Marianne Koller; Timo Wille
Journal:  Molecules       Date:  2020-07-02       Impact factor: 4.411

9.  Post-VX exposure treatment of rats with engineered phosphotriesterases.

Authors:  Lisa Stigler; Anja Köhler; Marianne Koller; Laura Job; Benjamin Escher; Heidrun Potschka; Horst Thiermann; Arne Skerra; Franz Worek; Timo Wille
Journal:  Arch Toxicol       Date:  2021-12-28       Impact factor: 5.153

10.  Advances in toxicology and medical treatment of chemical warfare nerve agents.

Authors:  Mohammd Moshiri; Emadodin Darchini-Maragheh; Mahdi Balali-Mood
Journal:  Daru       Date:  2012-11-28       Impact factor: 3.117

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.